Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + thalidomide + dexamethasone salvage and consolidation in transplant-eligible newly diagnosed multiple myeloma with suboptimal response to bortezomib induction
ACTRN12615000934549Phase 2Active, not recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Sep 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib, thalidomide, dexamethasone and melphalan in multiple myeloma (MM), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoints: Overall response rate before ASCT and Safety and tolerability of Car-TD salvage therapy. Started Sep 2016; status: active, not recruiting.
02
Drugs
carfilzomibthalidomidedexamethasonemelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12615000934549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000934549.